Mars Powder
Also known as: MARS therapy, Extracorporeal Liver Support System, Molecular Adsorbent Recirculating System (MARS)
Overview
The Molecular Adsorbent Recirculating System (MARS) is a medical device used as an extracorporeal liver support system for patients with acute liver failure (ALF) or acute-on-chronic liver failure (AOCLF). It is not a dietary supplement or derived from natural sources. MARS functions by removing albumin-bound toxins from the blood, mimicking the liver's detoxification processes. This is achieved through adsorption and dialysis, helping to clear substances like bilirubin, bile acids, and aromatic amino acids. The system is primarily used in clinical settings to support patients awaiting liver transplantation or those with potential for liver recovery. Research on MARS is mature, with numerous randomized controlled trials and meta-analyses assessing its efficacy, particularly in reducing mortality in ALF patients. It requires specialized medical administration and monitoring.
Benefits
The primary benefit of MARS therapy is a significant reduction in mortality for patients with acute liver failure (ALF). A meta-analysis of 10 randomized controlled trials demonstrated a 39% reduction in the risk of death compared to standard medical treatment (RR = 0.61, p = 0.04). However, no significant survival benefit has been observed in patients with acute-on-chronic liver failure (AOCLF) (RR = 0.88, p = 0.18). Secondary benefits include improvements in biochemical parameters related to liver function and toxin clearance, although the evidence for these is less consistent. The benefits are primarily seen during the acute treatment period, and long-term outcomes depend on the underlying liver disease and transplantation status.
How it works
MARS works by removing albumin-bound toxins from the patient's blood through extracorporeal albumin dialysis. The system recirculates the patient's blood through a specialized circuit that includes an albumin dialysate. This dialysate attracts and binds albumin-bound toxins such as bilirubin, bile acids, and aromatic amino acids, effectively clearing them from the bloodstream. By removing these toxins, MARS supports the liver's detoxification function, providing a temporary substitute for impaired hepatic clearance. This process helps to stabilize the patient's condition and improve their chances of survival or recovery.
Side effects
MARS therapy, while generally considered safe in appropriate clinical settings, is associated with several potential side effects. Common side effects (occurring in >5% of patients) include hypotension, bleeding complications due to the anticoagulation required during the procedure, and device-related infections. Uncommon side effects (1-5%) include electrolyte imbalances and thrombocytopenia. Rare side effects (<1%) may include severe allergic reactions to components of the system. Drug interactions can occur with anticoagulants used during MARS, potentially affecting other medications. Contraindications include severe hemodynamic instability and uncontrolled bleeding. Use in critically ill patients requires careful monitoring to mitigate these risks.
Dosage
MARS therapy involves treatment sessions that typically last 6-8 hours per day. The frequency of these sessions can vary, often administered daily or on alternate days, depending on the patient's clinical status and response to treatment. Early initiation of MARS therapy in acute liver failure may improve outcomes. As MARS is a device-based therapy, there are no form-specific recommendations or absorption factors to consider. The treatment requires anticoagulation and a specialized clinical setup. The maximum safe 'dose' is limited by the patient's tolerance and clinical response, necessitating close monitoring by medical professionals.
FAQs
Is Mars Powder a dietary supplement?
No, MARS refers to a medical liver support device, not a nutritional supplement. It is used in clinical settings for patients with liver failure.
Can MARS be self-administered?
No, MARS requires hospital-based administration by trained personnel due to the complexity of the procedure and the need for close monitoring.
What conditions benefit most from MARS?
Acute liver failure (ALF) patients have shown survival benefits with MARS therapy, as demonstrated in multiple randomized controlled trials.
Are there alternative treatments to MARS?
Yes, standard medical therapy and liver transplantation remain primary treatments for liver failure. MARS is often used as a bridge to these treatments.
Research Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4694195/ – This meta-analysis of 10 RCTs evaluated the efficacy of MARS therapy in patients with acute liver failure (ALF) and acute-on-chronic liver failure (AOCLF). The study found that MARS significantly reduced mortality in ALF patients (RR=0.61, p=0.04) but showed no significant survival benefit in AOCLF patients (RR=0.88, p=0.18).
- https://www.fda.gov/media/165090/download – This is a document from the FDA related to dietary supplements. It provides regulatory information and guidelines related to the manufacturing, labeling, and safety of dietary supplements. It does not directly relate to MARS therapy but provides context on supplement regulation.